2024
The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.
Althoff K, Stewart C, Humes E, Gerace L, Boyd C, Gebo K, Justice A, Hyle E, Coburn S, Lang R, Silverberg M, Horberg M, Lima V, Gill M, Karris M, Rebeiro P, Thorne J, Rich A, Crane H, Kitahata M, Rubtsova A, Wong C, Leng S, Marconi V, D'Souza G, Kim H, Napravnik S, McGinnis K, Kirk G, Sterling T, Moore R, Kasaie P. The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLOS Medicine 2024, 21: e1004325. PMID: 38215160, PMCID: PMC10833859, DOI: 10.1371/journal.pmed.1004325.Peer-Reviewed Original ResearchConceptsHistory of injection drug useInjection drug useHealthcare needsPrevalence of comorbiditiesHIV diagnosisNorth American AIDS Cohort CollaborationDrug useAntiretroviral therapyHIV surveillance dataGuideline-recommended careNon-Hispanic whitesPrevalence of anxietyChronic kidney diseaseMyocardial infarctionPrevalence of cancerEnd-stage liver diseaseResearch and DesignMultimorbidity prevalenceRisk of comorbiditiesUnited StatesBlack MSMNon-HispanicSubspecialty careClinical capacityHIV clinicians
2022
A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996–2020)
Smith A, Breazeale S, Goulet JL, Vlahov D, Justice AC, Womack JA. A Systematic Review of Risk Factors for Suicide Among Persons Living with HIV (1996–2020). AIDS And Behavior 2022, 26: 2559-2573. PMID: 35107660, DOI: 10.1007/s10461-022-03591-y.Peer-Reviewed Original ResearchConceptsRisk factorsHIV-specific risk factorsInjection drug useHIV-1 RNACause of morbidityShare risk factorsPrevious suicide attemptsQuantitative study designHIV diagnosisPeer-reviewed journalsHIV infectionEligible studiesInclusion criteriaPsychiatric illnessElevated riskGeneral populationAlcohol misuseElectronic databasesDrug useSystematic reviewSuicide attemptsStudy designInitial searchSearch termsHIV
2021
Brief original report: Does smoking status provide information relevant to screening for other substance use among US adults?
Khan MR, Ban K, Caniglia EC, Edelman JE, Gaither J, Crystal S, Chichetto NE, Young KE, Tate J, Justice AC, Braithwaite RS. Brief original report: Does smoking status provide information relevant to screening for other substance use among US adults? Preventive Medicine Reports 2021, 23: 101483. PMID: 34345578, PMCID: PMC8319511, DOI: 10.1016/j.pmedr.2021.101483.Peer-Reviewed Original ResearchInjection drug useUnhealthy alcohol useTobacco screeningDrug useSubstance useOpioid useStimulant useAlcohol useCrack/cocaine useIllicit opioid useCrack/cocaineTest performance characteristicsFormer smokersCurrent smokingSmoking statusUS adultsLifetime smokingCocaine useSmokingScreening resultsFour-fold decreaseNegative resultsMarijuana usePositive resultsTwo-fold decrease
2020
Mortality, Health, and Substance Abuse by Religious Attendance Among HIV Infected Patients from the Veterans Aging Cohort Study
Doolittle BR, McGinnis K, Ransome Y, Fiellin D, Justice A. Mortality, Health, and Substance Abuse by Religious Attendance Among HIV Infected Patients from the Veterans Aging Cohort Study. AIDS And Behavior 2020, 25: 653-660. PMID: 32902769, DOI: 10.1007/s10461-020-03028-4.Peer-Reviewed Original ResearchConceptsCohort studyVeterans Aging Cohort StudyAging Cohort StudyAssociation of mortalitySmall cohort studiesUnhealthy alcohol useOverall drug useHIV/AIDSSmoking statusMortality riskHigh social supportDrug useBiological markersSubstance abuseLess marijuana useAlcohol usePast yearReligious attendanceLower depressionMarijuana useMortalitySocial supportAssociationAttendanceHCV
2019
Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Althoff KN, Chandran A, Zhang J, Arevalo WM, Gange SJ, Sterling TR, Gill MJ, Justice AC, Palella FJ, Rebeiro PF, Silverberg MJ, Mayor AM, Horberg MA, Thorne JE, Rabkin CS, Mathews WC, Klein MB, Humes E, Lee J, Hogg R, Moore RD, Research and Design of IeDEA N. Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. American Journal Of Epidemiology 2019, 188: 2097-2109. PMID: 31602475, PMCID: PMC7036649, DOI: 10.1093/aje/kwz232.Peer-Reviewed Original ResearchConceptsAlcohol-related deathsInjection drug useKey populationsLife expectancyDrug useHuman immunodeficiency virusLife expectancy benefitAge 20 yearsCause of deathCurrent opioid epidemicAlcohol-related mortalityAntiretroviral treatmentImmunodeficiency virusOpioid epidemicExpected life expectancyWhite womenSubstance useWhite menComparison groupDrugsDeathPLWHLife expectancy disparityMenBlack men
2018
Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients
Gaither JR, Gordon K, Crystal S, Edelman EJ, Kerns RD, Justice AC, Fiellin DA, Becker WC. Racial disparities in discontinuation of long-term opioid therapy following illicit drug use among black and white patients. Drug And Alcohol Dependence 2018, 192: 371-376. PMID: 30122319, PMCID: PMC7106601, DOI: 10.1016/j.drugalcdep.2018.05.033.Peer-Reviewed Original ResearchConceptsLong-term opioid therapyIllicit drug useUrine drug testsDrug useOpioid therapyWhite racePositive urine drug testDrug testsMonths of treatmentElectronic medical recordsWhite patientsChronic painPatient raceMedical recordsPatientsLogistic regressionOpioidsRacial disparitiesDrug testingCocaineCannabisTherapyCliniciansDiscontinuationPainPast year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*
Khan MR, McGinnis KA, Grov C, Scheidell JD, Hawks L, Edelman EJ, Fiellin DA, McInnes DK, Braithwaite RS, Justice AC, Wang EA. Past year and prior incarceration and HIV transmission risk among HIV-positive men who have sex with men in the US*. AIDS Care 2018, 31: 349-356. PMID: 30064277, PMCID: PMC6699634, DOI: 10.1080/09540121.2018.1499861.Peer-Reviewed Original ResearchConceptsHIV-positive MSMSex risk behaviorsViral loadSubstance useDrug useRisk behaviorsNon-injection drug useTransmission riskMultiple sex partnershipsDetectable viral loadHIV viral loadHIV transmission riskInjection drug useNew HIV infectionsHIV-positive menPrior incarcerationHealth care programsHIV infectionClinical outcomesPast yearCare programSociodemographic factorsSocial determinantsRisk determinantsMSM
2017
DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty
Zhang X, Hu Y, Justice AC, Li B, Wang Z, Zhao H, Krystal JH, Xu K. DNA methylation signatures of illicit drug injection and hepatitis C are associated with HIV frailty. Nature Communications 2017, 8: 2243. PMID: 29269866, PMCID: PMC5740109, DOI: 10.1038/s41467-017-02326-1.Peer-Reviewed Original ResearchConceptsIllicit drug injectionHepatitis C infectionWhite blood cellsIllicit drug useCo-occurring conditionsMethylation signaturesDiscovery sampleC infectionHepatitis CEpigenome-wide association analysisLower frailtyDrug injectionHigh frailtyImmune functionHealth outcomesDrug useFrailtyDNA methylation signaturesBlood cellsHIVReplication sampleEpigenetic programmingSignificant CpGsEpigenetic effectsIndividuals
2016
Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy
Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, Boesecke C, Samji H, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, Smit C, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice AC, Sterling T, Miro J, Ingle S, Sterne JA, Collaboration A. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLOS ONE 2016, 11: e0160460. PMID: 27525413, PMCID: PMC4985160, DOI: 10.1371/journal.pone.0160460.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyLow CD4 countHIV-positive patientsAntiretroviral therapyCD4 countDrug useAntiretroviral Therapy Cohort CollaborationFive-year mortality riskAIDS infectionOlder ageCause-specific mortality rate ratiosNon-AIDS cancerLiver-related mortalityHIV Cohort StudyInjection drug useHIV-1 RNAMortality rate ratiosLiver-related diseasesHigh subsequent mortalityCohort CollaborationLow CD4Prior AIDSCardiovascular mortalityCohort studyPrognostic factors
2015
Quality of HIV Care and Mortality Rates in HIV-Infected Patients
Korthuis PT, McGinnis KA, Kraemer KL, Gordon AJ, Skanderson M, Justice AC, Crystal S, Goetz MB, Gibert CL, Rimland D, Fiellin LE, Gaither JR, Wang K, Asch SM, McInnes DK, Ohl ME, Bryant K, Tate JP, Duggal M, Fiellin DA. Quality of HIV Care and Mortality Rates in HIV-Infected Patients. Clinical Infectious Diseases 2015, 62: 233-239. PMID: 26338783, PMCID: PMC4690479, DOI: 10.1093/cid/civ762.Peer-Reviewed Original ResearchConceptsMortality rateIllicit drug useDrug useSurvival analysisDisease severityNational Death Index recordsVeterans Aging Cohort StudyKaplan-Meier survival analysisCox proportional hazards modelAge-adjusted mortality ratesPast-year illicit drug useAging Cohort StudyOverall mortality rateHuman immunodeficiency virusVeterans Health AdministrationUnhealthy alcohol useProportional hazards modelLower age-adjusted mortality ratesHigh-quality careLongitudinal survival analysisHIV qualityUnhealthy alcoholHIV careCohort studyImproved survivalInjection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals
May MT, Justice AC, Birnie K, Ingle SM, Smit C, Smith C, Neau D, Guiguet M, Schwarze-Zander C, Moreno S, Guest JL, Monforte A, Tural C, Gill MJ, Bregenzer A, Kirk O, Saag M, Sterling TR, Crane HM, Sterne JA. Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 348-354. PMID: 25848927, PMCID: PMC4506784, DOI: 10.1097/qai.0000000000000603.Peer-Reviewed Original ResearchConceptsInjection drug useDrug useLiver-related mortalityHepatitis C infectionEffect of HCVMortality hazard ratioNorth American cohortHCV coinfectionHCV statusAntiretroviral therapyC infectionHepatitis CHazard ratioSurvival differencesRisk factorsExcess mortalityPoor survivalRisk groupsHCVAmerican cohortHIVNew treatmentsMortalitySubstantial proportionComplete dataIncarceration and health outcomes in HIV‐infected patients: The impact of substance use, primary care engagement, and antiretroviral adherence
Wang EA, McGinnis KA, Long JB, Akgün KM, Edelman EJ, Rimland D, Wang KH, Justice AC, Fiellin DA. Incarceration and health outcomes in HIV‐infected patients: The impact of substance use, primary care engagement, and antiretroviral adherence. American Journal On Addictions 2015, 24: 178-184. PMID: 25662297, PMCID: PMC4397180, DOI: 10.1111/ajad.12177.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHistory of incarcerationHIV disease outcomeVACS Index scorePrimary care engagementAntiretroviral adherenceCare engagementDisease outcomeIndex scoreDrug useHigher VACS Index scoresHealth of HIVAging Cohort StudyUnhealthy alcohol useViral RNA loadRecent drug useLow CD4Cohort studyRNA loadDrug treatmentHIVHealth outcomesMultivariate analysisMediation analysisPatients
2013
Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada
Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, Research and Design of IeDEA F. Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLOS ONE 2013, 8: e81355. PMID: 24367482, PMCID: PMC3867319, DOI: 10.1371/journal.pone.0081355.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive adultsMortality rateLife expectancyNorth American AIDS Cohort CollaborationHIV transmission risk groupTransmission risk groupsCombination antiretroviral therapyInjection drug useHIV-positive individualsCrude mortality rateComparable life expectancyBaseline CD4Cohort CollaborationART initiationCD4 countAge-specific mortality ratesRisk groupsPositive adultsGeneral populationDrug useAge 20Cells/AdultsAdditional yearCohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)
May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne J, Collaboration T. Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). International Journal Of Epidemiology 2013, 43: 691-702. PMID: 23599235, PMCID: PMC4052127, DOI: 10.1093/ije/dyt010.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAge FactorsAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveBiomarkersCD4 Lymphocyte CountCohort StudiesCoinfectionEuropeFemaleHIV InfectionsHumansLife ExpectancyNorth AmericaPregnancyPrognosisResidence CharacteristicsRisk FactorsSex FactorsSocioeconomic FactorsTime FactorsViral LoadConceptsAntiretroviral Therapy Cohort CollaborationCombination antiretroviral therapyAntiretroviral therapyCohort CollaborationHIV biomarkersCohort studyClinical eventsHuman immunodeficiency virus-infected individualsEffective combination antiretroviral therapyIndividual cohort studiesVirus-infected individualsHIV Cohort StudyHIV-1 infectionImmune deficiency syndromeCause of deathART regimenHepatitis CAdult patientsAIDS eventsPatient demographicsRisk factorsDeficiency syndromeLiver enzymesPrognostic analysisDrug use
2012
Unhealthy Alcohol and Illicit Drug Use Are Associated With Decreased Quality of HIV Care
Korthuis PT, Fiellin DA, McGinnis KA, Skanderson M, Justice AC, Gordon AJ, Doebler DA, Asch SM, Fiellin LE, Bryant K, Gibert CL, Crystal S, Goetz MB, Rimland D, Rodriguez-Barradas MC, Kraemer KL. Unhealthy Alcohol and Illicit Drug Use Are Associated With Decreased Quality of HIV Care. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2012, 61: 171-178. PMID: 22820808, PMCID: PMC3460799, DOI: 10.1097/qai.0b013e31826741aa.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useIllicit drug useDrug useAlcohol useUnhealthy alcoholHIV careCohort studySubstance useVeterans Aging Cohort StudyRetrospective cohort studyAging Cohort StudySuboptimal health outcomesMultivariable linear regressionSubstance use dataVeteran patientsMean ageMedical recordsMultivariable modelDecreased qualityMAIN OUTCOMEPatientsHealth outcomesHIVMean percentageQuality indicators
2011
Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening
Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. The Journal Of Infectious Diseases 2011, 204: 893-901. PMID: 21849286, PMCID: PMC3156918, DOI: 10.1093/infdis/jir421.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) initiationAntiretroviral therapy initiationInjection drug useHIV-1 RNAHuman immunodeficiency virusHAART initiationTuberculosis riskBaseline CD4Therapy initiationMale sexNonwhite raceHispanic ethnicityDrug useBaseline HIV-1 RNAMonths of HAARTLow-incidence settingsProportional hazards modelActive tuberculosisLymphocyte countParametric survival modelsTuberculosis screeningImmunodeficiency virusBlack raceLymphocytes/Risk factors
2010
Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens in HIV-Infected and Uninfected Current Smokers
Crothers K, Daly KR, Rimland D, Goetz MB, Gibert CL, Butt AA, Justice AC, Djawe K, Levin L, Walzer PD. Decreased Serum Antibody Responses to Recombinant Pneumocystis Antigens in HIV-Infected and Uninfected Current Smokers. MSphere 2010, 18: 380-386. PMID: 21191078, PMCID: PMC3067379, DOI: 10.1128/cvi.00421-10.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusChronic obstructive pulmonary diseaseAntibody responseEnzyme-linked immunosorbent assayP. jiroveciiCurrent smokersSerum antibodiesHIV-negative subjectsObstructive pulmonary diseaseInjection drug useSerum antibody responseMultivariate Tobit regression modelsHazardous alcohol useCross-sectional analysisUninfected patientsCurrent smokingHIV infectionIndependent predictorsPulmonary diseaseSyncytial virusImmunosuppressive effectsSerologic studiesSubsequent riskPneumocystis jiroveciiDrug usePatterns of drug use and abuse among aging adults with and without HIV: A latent class analysis of a US Veteran cohort
Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, Gordon AJ, Maisto SA, Day NL, Bryant K, Fiellin DA, Justice AC. Patterns of drug use and abuse among aging adults with and without HIV: A latent class analysis of a US Veteran cohort. Drug And Alcohol Dependence 2010, 110: 208-220. PMID: 20395074, PMCID: PMC3087206, DOI: 10.1016/j.drugalcdep.2010.02.020.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyHIV statusMultidrug usersDrug useLatent class analysisUS Veteran cohortAging Cohort StudyActive drug useSelf-reported drug useMental health disordersProblem of obesityElectronic medical recordsUninfected veteransCohort studyClinical variablesDrug use consequencesSocio-demographic covariatesMedical recordsHigh prevalenceUninfected adultsAge 50HIVHealth disordersDrug usersVeteran cohort
2008
Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV
Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV. Value In Health 2008, 11: 975-979. PMID: 18225989, PMCID: PMC3121315, DOI: 10.1111/j.1524-4733.2007.00315.x.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyBothersome symptomsSF-6D utilitiesAntiretroviral therapyCD4 countSide effectsVeterans Aging Cohort StudyAging Cohort StudySF-12 scoresAfrican American raceHazardous alcohol consumptionQuality of lifeRecent drug useCART initiationMild anginaCohort studyMultivariable analysisCigarette smokingUnivariate analysisAmerican raceAlcohol consumptionDrug useUtility decrementsPatientsClinical decision
2007
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies
May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, D'Arminio Monforte A, Schmeisser N, Staszewski S, Egger M. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007, 21: 1185-1197. PMID: 17502729, PMCID: PMC3460385, DOI: 10.1097/qad.0b013e328133f285.Peer-Reviewed Original ResearchConceptsStart of HAARTCD4 cell countCell countHIV-1 RNA levelsHIV-1-infected patientsInitiation of HAARTTreatment-naive patientsDiagnosis of AIDSInjection drug useVirological responseHIV careNew AIDSCumulative incidenceParametric survival modelsClinical stageProspective studyRisk calculatorHAARTProgression rateTreatment changesPatientsDrug usePrognostic modelAIDSCells/